IL6 and neoplasm: Identifying senescent tumor cells through robust biomarkers, such as the cyclin-dependent kinase inhibitors p16INK4A and p21CIP1, along with SASP indicators characterized by elevated interleukins (IL-6, IL-8) and chemokines like CXCL1 [102,110,111], provides critical insights into the underlying biology of these cancers.